GlassScriptPhysician profile
Bernard S Zeffren
NPI 1982609046
$6,440.49
in general payments reported to CMS, 2019-2025
24 companies · $1,005 in 2025
The $1,005 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $631 · 2020: $420 · 2021: $1,010 · 2022: $1,188 · 2023: $1,299 · 2024: $887 · 2025: $1,005.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,191.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,300.98 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Regeneron Healthcare Solutions, INC. | $845.75 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $669.02 | 2019-2024 | Nucala |
| Novartis Pharmaceuticals Corporation | $538.41 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $495.73 | 2020-2025 | Takhzyro, Hyqvia, Cuvitru |
| Csl Behring | $352.65 | 2019-2025 | Hizentra, Haegarda |
| Blueprint Medicines Corporation | $313.05 | 2023-2024 | Ayvakit |
| Genentech USA, INC. | $229.01 | 2019-2025 | Xolair |
| Grifols USA, LLC | $199.69 | 2019-2025 | Xembify |
| Kaleo, INC. | $190.49 | 2019-2024 | Auvi-Q |
| Optinose US, INC. | $176.11 | 2019-2023 | |
| Genzyme Corporation | $173.03 | 2019-2025 | |
| Pfizer INC. | $147.60 | 2019-2025 | |
| Pharming Healthcare, INC. | $136.66 | 2020-2025 | Ruconest |
| Teva Pharmaceuticals USA, INC. | $135.62 | 2020-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $115.79 | 2019-2025 | Odactra, Grastek, Ragwitek |
| Amgen INC. | $97.60 | 2022-2024 | Tezspire |
| Ars Pharmaceuticals Operations, INC. | $80.04 | 2025 | Neffy |
| Shire North American Group INC | $65.23 | 2019 | |
| Greer Laboratories, INC. | $57.77 | 2019-2024 | Oralair |
| Merck Sharp & Dohme LLC | $51.14 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.13 | 2019-2020 | |
| Horizon Therapeutics Plc | $22.04 | 2020 | |
| Hikma Pharmaceuticals USA | $16.95 | 2023 | Ryaltris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bernard Zeffren listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.